Seven Firms Advise on Mylan's $1.6 Billion Generic Drug Buy

, The Am Law Daily


Global generic drug and specialty pharmaceuticals maker Mylan has turned to Skadden, Arps, Slate, Meagher & Flom, Magic Circle shop Slaughter and May, and Indian firm Platinum Partners for counsel on its $1.6 billion acquisition of Indian generic injectable drug manufacturer Agila Specialties from parent Strides Arcolab. Haynes and Boone, Herbert Smith Freehills, and firms from Brazil and India are advising the seller.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Continue to Lexis Advance®

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202590481985

Thank you!

This article's comments will be reviewed.